Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
IMO, your “read” is exactly as the company intended the PR to be read, regardless of how tortured a read it may have been.
Sure… okay.
Let’s circle back to this mid-Dec.
Haha... I don't agree, and I think you'll be the one that remains.
Most of the work the company had noted was still being worked on as of 10/13 is completed, as per the PR.
More months than one.
Yes... I meant to write "several" usually indicates 3 up to the next description... such as a dozen, or many... and in this case, I think month (being that it would be four weeks or more) would be the next descriptive.
In the context of weeks, it should mean around 3 weeks… otherwise, they should have indicated a month (4 weeks) or so.
Few usually indicates about two, and three usually indicates 3 up to the next description (e.g. dozen, or month).
Thanks Doc! :)
I was frustrated (and irritated) on 10/13. But after 11 years of this, I'm quite used (and almost immune) to it.
I will say that I suspect we will hear before January, though. I will be very, very surprised (and irritated, again) if we don't.
Gary, may you and your wife both live very long without dementia but instead sharp as tacks!
I do t doubt the RNA path won’t be pursued, especially after Covid. It worked so well in ensuring we didn’t get it after receiving the shot… oh wait… no it didn’t. Maybe it made our covid experience less likely to end in death, maybe it didn’t. What I remember is that Merck had partnered with Moderna to pursue RNA and then pulled out of that partnership pre-Covid (why?), and now they’re partnering with them again.
A truly autologous cancer vaccine cannot be reproduced on the shelf and costs a fortune to make and take to trial (as we all well know). But it stands to reason that the more of whatever’s in one’s own tumor that one can target using one’s own body’s defenses to do it, the more likely there will be a successful outcome.
On that note, the rindopepimut vaccine trialed in GBM targeted EGRF3, and when used in the treatment, the tumor came back, usually sans the EGRF3.
Nice analogy and description of the differences between RNA and an entirely autologous cancer vaccine. :)
Most will show by 3 months, so not "many", otherwise, why go with a three month screen?
And most of the other trials only noted that they excluded rapid progressors and not the psPD patients.
RNA vaccines would not be nearly as personalized as DCVax - which uses the patient's own tumor and own blood to create a completely autologous vaccine. Good find, tho. :)
Hmm... not sure exactly what you're trying to say.
Except for here...
I would think that the regulators will have access to the original randomized OS results as well, and they can decide what they think the numbers indicate then.
The problem with the progression endpoint, too, was that determining progression in the DCVax trial was clearly spelled out in the protocol using a quickly outdated (certainly by 2012) method. It’s unfortunate that method was never able to be changed.
OS is really all that counts, don’t you think? I’m sure patients would agree. :)
The share price was dropping like a rock before the presentation even began, let alone the PFS slide was shone.
Don’t you remember there was a YouTube video of a shareholder showing the share price tanking next to the presentation (that hadn’t even begun!) screen? That video (captured, I’m sure, by Northwest), will come in handy should the defense use “play that angle”.
Good approach, Captain! :)
Agreed, Mike. Looks like you’re long. Disgruntled, but long.
Or finance future trials.
First time, I think, that we’ve ever agreed on something? :)
Interesting.
lawsuit related.
Lol... I just saw this! Good one! :)
Good DD. :)
There are some who might say the FUD begins at the corner of Southeast 2nd Street and South Biscayne Blvd. in Miami (Citadel headquarters).
:)
There's still lots of work to be done... and then we'll take it higher. :)
That’s close to what I’m thinking as well.
Agreed. :)
Was it Henry’s post on Twitter re: the murcidencel name?
Brand Institute is, "The global leader in USAN/INN naming, partnering on 76% of USAN and 78% of INN drug name approvals!" #murcidencel #DCVax-L $NWBOhttps://t.co/u9BpJTBrf4 pic.twitter.com/u0zIUYYR9i
— Henry (@HenryMuney) October 27, 2023
I think he never went to college.
A revisit and a relook… that was actually rather clever.
My average is around .45 so I’m definitely in the money.
Have you?